Patent · US Active

Osteoclast inhibitors for knee conditions

US9289384B2 · kind B2 · utility

82Cited by

6References

13Claims

0Family size

Assignee

ANTECIP BIOVENTURES II LLC · US

Inventors

Herriot Tabuteau · New York, US
Graeme Jones · Hobart, AU

Key dates

Filing date	Jan 28, 2015
Grant date	Mar 22, 2016
Priority date	—
Expiry date	Jan 28, 2035

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K45/06
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, can be used to treat or alleviate pain or related conditions.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.